D
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Price:
16 710
KRW
2.26%
Market Closed
Market Cap:
734.6B
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Dongkook Pharmaceutical Co Ltd
16710
+370 (+2.26%)
| 52 Week Range |
15 680
19 470
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Dongkook Pharmaceutical Co Ltd
Income Statement
Earnings Waterfall
Dongkook Pharmaceutical Co Ltd
Dongkook Pharmaceutical Co Ltd
|
Revenue
|
789.1B
KRW
|
|
Cost of Revenue
|
-350B
KRW
|
|
Gross Profit
|
439.1B
KRW
|
|
Operating Expenses
|
-355.8B
KRW
|
|
Operating Income
|
83.2B
KRW
|
|
Other Expenses
|
-21.6B
KRW
|
|
Net Income
|
61.7B
KRW
|
Income Statement
Dongkook Pharmaceutical Co Ltd
Dongkook Pharmaceutical Co Ltd
Currency: KRW
| Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Revenue |
224 391
N/A
|
226 014
+1%
|
228 198
+1%
|
234 687
+3%
|
244 766
+4%
|
259 930
+6%
|
275 174
+6%
|
292 760
+6%
|
302 007
+3%
|
309 690
+3%
|
320 349
+3%
|
330 629
+3%
|
342 293
+4%
|
354 768
+4%
|
366 905
+3%
|
378 387
+3%
|
391 800
+4%
|
400 807
+2%
|
418 583
+4%
|
436 293
+4%
|
456 230
+5%
|
482 280
+6%
|
502 390
+4%
|
520 469
+4%
|
544 685
+5%
|
559 103
+3%
|
572 390
+2%
|
588 359
+3%
|
585 740
0%
|
594 193
+1%
|
615 974
+4%
|
631 065
+2%
|
645 744
+2%
|
661 647
+2%
|
676 772
+2%
|
692 794
+2%
|
709 543
+2%
|
730 994
+3%
|
747 013
+2%
|
764 673
+2%
|
789 114
+3%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(95 575)
|
(98 041)
|
(99 097)
|
(102 533)
|
(105 870)
|
(111 578)
|
(115 214)
|
(120 762)
|
(124 611)
|
(126 781)
|
(132 120)
|
(136 043)
|
(139 273)
|
(145 412)
|
(151 522)
|
(155 139)
|
(160 383)
|
(162 858)
|
(169 097)
|
(175 871)
|
(183 440)
|
(191 445)
|
(198 389)
|
(205 265)
|
(213 813)
|
(221 694)
|
(227 674)
|
(236 998)
|
(240 243)
|
(243 933)
|
(256 244)
|
(264 210)
|
(270 754)
|
(281 822)
|
(291 152)
|
(300 870)
|
(310 064)
|
(320 213)
|
(327 915)
|
(337 031)
|
(350 035)
|
|
| Gross Profit |
128 816
N/A
|
127 974
-1%
|
129 100
+1%
|
132 153
+2%
|
138 895
+5%
|
148 352
+7%
|
159 959
+8%
|
171 997
+8%
|
177 395
+3%
|
182 909
+3%
|
188 229
+3%
|
194 585
+3%
|
203 019
+4%
|
209 356
+3%
|
215 382
+3%
|
223 248
+4%
|
231 417
+4%
|
237 949
+3%
|
249 486
+5%
|
260 422
+4%
|
272 789
+5%
|
290 835
+7%
|
304 000
+5%
|
315 203
+4%
|
330 872
+5%
|
337 410
+2%
|
344 717
+2%
|
351 362
+2%
|
345 497
-2%
|
350 260
+1%
|
359 730
+3%
|
366 856
+2%
|
374 990
+2%
|
379 826
+1%
|
385 620
+2%
|
391 925
+2%
|
399 479
+2%
|
410 781
+3%
|
419 099
+2%
|
427 641
+2%
|
439 079
+3%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(102 084)
|
(101 419)
|
(103 360)
|
(106 595)
|
(110 589)
|
(114 742)
|
(122 305)
|
(127 942)
|
(132 136)
|
(135 983)
|
(140 092)
|
(148 179)
|
(155 887)
|
(159 285)
|
(163 740)
|
(168 995)
|
(173 386)
|
(182 834)
|
(192 595)
|
(201 971)
|
(212 383)
|
(222 250)
|
(230 591)
|
(238 519)
|
(247 048)
|
(252 676)
|
(259 708)
|
(268 824)
|
(276 682)
|
(287 041)
|
(292 709)
|
(295 660)
|
(303 468)
|
(307 172)
|
(317 064)
|
(330 422)
|
(335 645)
|
(343 908)
|
(350 521)
|
(352 750)
|
(355 849)
|
|
| Selling, General & Administrative |
(92 040)
|
(91 193)
|
(92 722)
|
(95 877)
|
(99 947)
|
(104 265)
|
(111 161)
|
(117 152)
|
(121 475)
|
(125 188)
|
(130 082)
|
(137 271)
|
(143 713)
|
(145 976)
|
(148 815)
|
(152 719)
|
(157 349)
|
(165 834)
|
(174 923)
|
(182 535)
|
(190 249)
|
(199 245)
|
(207 045)
|
(215 523)
|
(224 472)
|
(230 420)
|
(237 354)
|
(245 591)
|
(249 859)
|
(258 083)
|
(261 987)
|
(263 937)
|
(273 431)
|
(279 435)
|
(289 111)
|
(301 649)
|
(306 898)
|
(312 714)
|
(317 656)
|
(318 860)
|
(320 341)
|
|
| Research & Development |
(9 407)
|
(9 621)
|
(10 089)
|
(10 161)
|
(10 178)
|
(10 099)
|
(10 801)
|
(10 470)
|
(10 312)
|
(10 415)
|
(9 621)
|
(10 500)
|
(11 730)
|
(12 788)
|
(14 287)
|
(15 531)
|
(15 186)
|
(15 960)
|
(16 044)
|
(17 273)
|
(19 407)
|
(19 890)
|
(20 445)
|
(19 883)
|
(19 468)
|
(18 859)
|
(18 877)
|
(19 590)
|
(22 519)
|
(24 691)
|
(26 376)
|
(27 156)
|
(25 748)
|
(23 105)
|
(23 036)
|
(23 600)
|
(23 514)
|
(25 456)
|
(26 786)
|
(27 439)
|
(28 482)
|
|
| Depreciation & Amortization |
(638)
|
(606)
|
(549)
|
(557)
|
(463)
|
(379)
|
(344)
|
(322)
|
(352)
|
(380)
|
(393)
|
(412)
|
(448)
|
(522)
|
(642)
|
(749)
|
(854)
|
(1 040)
|
(1 630)
|
(2 165)
|
(2 729)
|
(3 115)
|
(3 104)
|
(3 115)
|
(3 111)
|
(3 398)
|
(3 509)
|
(3 665)
|
(4 329)
|
(4 266)
|
(4 346)
|
(4 567)
|
(4 288)
|
(4 632)
|
(4 917)
|
(5 173)
|
(5 233)
|
(5 738)
|
(6 078)
|
(6 452)
|
(7 026)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
4
|
4
|
4
|
0
|
4
|
4
|
3
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
3
|
0
|
32
|
23
|
25
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
26 730
N/A
|
26 554
-1%
|
25 739
-3%
|
25 557
-1%
|
28 305
+11%
|
33 610
+19%
|
37 653
+12%
|
44 054
+17%
|
45 259
+3%
|
46 926
+4%
|
48 137
+3%
|
46 406
-4%
|
47 132
+2%
|
50 071
+6%
|
51 642
+3%
|
54 253
+5%
|
58 031
+7%
|
55 115
-5%
|
56 890
+3%
|
58 450
+3%
|
60 405
+3%
|
68 585
+14%
|
73 409
+7%
|
76 684
+4%
|
83 824
+9%
|
84 734
+1%
|
85 009
+0%
|
82 539
-3%
|
68 815
-17%
|
63 219
-8%
|
67 021
+6%
|
71 195
+6%
|
71 522
+0%
|
72 654
+2%
|
68 556
-6%
|
61 503
-10%
|
63 834
+4%
|
66 873
+5%
|
68 578
+3%
|
74 891
+9%
|
83 230
+11%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
1 153
|
1 389
|
1 339
|
2 058
|
1 744
|
1 742
|
1 641
|
1 257
|
3 252
|
5 814
|
4 558
|
5 102
|
3 573
|
952
|
2 585
|
3 325
|
2 971
|
6 868
|
6 887
|
6 601
|
8 097
|
5 120
|
7 087
|
6 361
|
5 155
|
(446)
|
(2 007)
|
(2 916)
|
(1 844)
|
7 744
|
5 447
|
4 819
|
5 431
|
(3 776)
|
(1 793)
|
(1 568)
|
(2 471)
|
(4 939)
|
(1 132)
|
(2 155)
|
668
|
|
| Non-Reccuring Items |
(431)
|
(389)
|
(387)
|
(112)
|
(111)
|
(13)
|
(11)
|
(11)
|
(11)
|
(11)
|
(12)
|
(12)
|
(12)
|
(11)
|
(12)
|
(12)
|
(12)
|
(11)
|
(189)
|
(189)
|
(189)
|
(11)
|
165
|
165
|
165
|
(11)
|
(12)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
53
|
57
|
26
|
22
|
11
|
11
|
(4)
|
15
|
15
|
22
|
0
|
0
|
8
|
331
|
436
|
539
|
506
|
432
|
327
|
244
|
276
|
(341)
|
(338)
|
(369)
|
(365)
|
(2)
|
(77)
|
(68)
|
(70)
|
966
|
1 630
|
1 659
|
1 656
|
619
|
26
|
(1)
|
751
|
753
|
753
|
849
|
99
|
|
| Total Other Income |
1 313
|
800
|
875
|
925
|
721
|
1 441
|
1 483
|
1 530
|
1 588
|
1 382
|
1 234
|
1 243
|
1 100
|
1 448
|
1 248
|
1 067
|
654
|
703
|
1 012
|
1 556
|
2 381
|
2 276
|
2 243
|
880
|
176
|
(4 243)
|
(4 723)
|
(4 673)
|
(3 816)
|
(2 176)
|
(2 494)
|
(2 349)
|
(2 793)
|
(864)
|
(427)
|
(615)
|
(2 021)
|
(1 850)
|
(2 685)
|
(2 350)
|
(1 229)
|
|
| Pre-Tax Income |
28 818
N/A
|
28 412
-1%
|
27 591
-3%
|
28 450
+3%
|
30 670
+8%
|
36 791
+20%
|
40 763
+11%
|
46 845
+15%
|
50 103
+7%
|
54 133
+8%
|
53 917
0%
|
52 739
-2%
|
51 801
-2%
|
52 790
+2%
|
55 901
+6%
|
59 172
+6%
|
62 150
+5%
|
63 107
+2%
|
64 927
+3%
|
66 663
+3%
|
70 970
+6%
|
75 629
+7%
|
82 566
+9%
|
83 722
+1%
|
88 957
+6%
|
80 031
-10%
|
78 190
-2%
|
74 882
-4%
|
63 086
-16%
|
69 754
+11%
|
71 605
+3%
|
75 324
+5%
|
75 816
+1%
|
68 632
-9%
|
66 361
-3%
|
59 319
-11%
|
60 093
+1%
|
60 838
+1%
|
65 514
+8%
|
71 235
+9%
|
82 768
+16%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
(10 880)
|
(7 415)
|
(6 930)
|
(7 036)
|
(7 618)
|
(9 564)
|
(10 387)
|
(11 745)
|
(12 036)
|
(13 440)
|
(13 480)
|
(12 848)
|
(12 697)
|
(11 923)
|
(12 511)
|
(13 478)
|
(14 242)
|
(13 674)
|
(13 054)
|
(13 586)
|
(14 507)
|
(16 579)
|
(19 544)
|
(19 556)
|
(22 768)
|
(22 150)
|
(22 008)
|
(21 509)
|
(19 209)
|
(16 837)
|
(18 309)
|
(17 130)
|
(14 009)
|
(13 876)
|
(11 292)
|
(10 133)
|
(10 397)
|
(11 966)
|
(12 779)
|
(15 933)
|
(18 717)
|
|
| Income from Continuing Operations |
17 938
|
20 997
|
20 661
|
21 414
|
23 052
|
27 227
|
30 376
|
35 100
|
38 068
|
40 693
|
40 438
|
39 891
|
39 103
|
40 868
|
43 389
|
45 695
|
47 909
|
49 433
|
51 874
|
53 077
|
56 463
|
59 050
|
63 022
|
64 166
|
66 188
|
57 880
|
56 181
|
53 372
|
43 878
|
52 916
|
53 296
|
58 194
|
61 808
|
54 757
|
55 069
|
49 186
|
49 696
|
48 871
|
52 734
|
55 302
|
64 050
|
|
| Income to Minority Interest |
168
|
102
|
149
|
(34)
|
87
|
199
|
113
|
92
|
34
|
(33)
|
(15)
|
107
|
(1 032)
|
(1 266)
|
(1 695)
|
(2 824)
|
(2 215)
|
(2 484)
|
(2 717)
|
(2 459)
|
(2 666)
|
(2 738)
|
(2 662)
|
(2 596)
|
(2 686)
|
(1 955)
|
(1 665)
|
(888)
|
67
|
(2 571)
|
(2 376)
|
(2 583)
|
(2 864)
|
(1 861)
|
(1 839)
|
(2 029)
|
(2 222)
|
(1 696)
|
(1 910)
|
(810)
|
(2 396)
|
|
| Net Income (Common) |
18 106
N/A
|
21 098
+17%
|
20 810
-1%
|
21 379
+3%
|
23 139
+8%
|
27 426
+19%
|
30 488
+11%
|
35 192
+15%
|
38 100
+8%
|
40 660
+7%
|
40 421
-1%
|
39 996
-1%
|
38 070
-5%
|
39 602
+4%
|
41 695
+5%
|
42 872
+3%
|
45 695
+7%
|
46 949
+3%
|
49 157
+5%
|
50 618
+3%
|
53 797
+6%
|
56 312
+5%
|
60 360
+7%
|
61 569
+2%
|
63 501
+3%
|
55 925
-12%
|
54 515
-3%
|
52 484
-4%
|
43 945
-16%
|
50 345
+15%
|
50 919
+1%
|
55 611
+9%
|
58 943
+6%
|
52 896
-10%
|
53 230
+1%
|
47 157
-11%
|
47 474
+1%
|
47 175
-1%
|
50 824
+8%
|
54 492
+7%
|
61 654
+13%
|
|
| EPS (Diluted) |
411.5
N/A
|
479.5
+17%
|
472.95
-1%
|
485.88
+3%
|
525.88
+8%
|
623.31
+19%
|
692.9
+11%
|
799.81
+15%
|
865.9
+8%
|
924.09
+7%
|
918.65
-1%
|
909
-1%
|
865.22
-5%
|
900.04
+4%
|
947.61
+5%
|
974.36
+3%
|
1 038.52
+7%
|
1 067.02
+3%
|
1 092.37
+2%
|
1 124.84
+3%
|
1 195.48
+6%
|
1 251.37
+5%
|
1 341.33
+7%
|
1 368.2
+2%
|
1 411.13
+3%
|
1 242.77
-12%
|
1 211.44
-3%
|
1 173.64
-3%
|
982.69
-16%
|
1 125.82
+15%
|
1 138.65
+1%
|
1 243.39
+9%
|
1 317.88
+6%
|
1 182.73
-10%
|
1 190.15
+1%
|
1 054.2
-11%
|
1 061.28
+1%
|
1 054.64
-1%
|
1 136.17
+8%
|
1 218
+7%
|
1 378.09
+13%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
